Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Breast Cancer

Free Subscription 17.11.2025 2 Am J Surg 2 Ann Surg 6 BMC Cancer 1 Br J Cancer 1 Breast Cancer (Dove Med Press) 5 Breast Cancer Res 1 Cancer Lett 2 Cancer Res 4 Clin Breast Cancer 2 Clin Cancer Res 2 Eur J Cancer 3 Histopathology 1 J Clin Oncol 3 J Natl Cancer Inst 2 J Pathol 1 Nat Rev Clin Oncol 3 NPJ Breast Cancer 2 Oncogene 3 PLoS One 3 Proc Natl Acad Sci U S A 1 Radiol Artif Intell 1 Radiologia (Engl Ed) 1 Radiother Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Surg

1. NIERENBERG TC, Dalton JC, Howell R, Kaplan S, et al
   Risk assessment tools for women with breast atypia: A systematic review.
   Am J Surg. 2025;250:116598.
   PubMed         Abstract available
   
   
2. CHEN DY, Ludwigson A, Higgins MG, Leslie SE, et al
   MedEd: An innovative approach to enhance patient comprehension and interpretation of a sample mammography report.
   Am J Surg. 2025;250:116643.
   PubMed         Abstract available
   
   

   
   Ann Surg

3. WAGNER BD, Barrio AV, Coriddi MR, Rubin J, et al
   Redefining the Diagnostic Threshold for Breast Cancer-related Lymphedema.
   Ann Surg. 2025 Nov 12. doi: 10.1097/SLA.0000000000006983.
   PubMed         Abstract available
   
   
4. HADZIKADIC-GUSIC L, Bilz J, Boselli D, Symanowski J, et al
   A Randomized, Single-Center, Superiority Trial of Radioactive Seed Localization Versus Wire Localization for Malignant Breast Disease.
   Ann Surg. 2025;282:998-1006.
   PubMed         Abstract available
   
   

   
   BMC Cancer

5. LIU J, Leng X, Yuan Z, Li Y, et al
   Predicting breast cancer response to neoadjuvant chemotherapy with ultrasound-based deep learning radiomics models -- dual-center study.
   BMC Cancer. 2025;25:1737.
   PubMed         Abstract available
   
   
6. SECA M, Gronwald J, Huzarski T, Glass K, et al
   Treatment of infertility and risk of breast cancer among women with a BRCA pathogenic variant: a matched case-control study.
   BMC Cancer. 2025;25:1740.
   PubMed         Abstract available
   
   
7. MONKAM P, Wang X, Zhao B, Qi S, et al
   Efficient temporal feature utilization in ultrasound videos: a multi-channel deep learning framework for enhanced breast lesion differentiation.
   BMC Cancer. 2025;25:1744.
   PubMed         Abstract available
   
   
8. VENGHATERI JB, Nathani P, Goyal S, Sarang B, et al
   Low participation in cancer screening in India: a scoping review of breast and cervical cancer programs.
   BMC Cancer. 2025;25:1724.
   PubMed         Abstract available
   
   
9. ZHANG Y, Cai J, Cui C, Qi S, et al
   Predicting breast cancer response to neoadjuvant therapy by integrating radiomic and deep-learning features from early-and-peak phases of DCE-MRI.
   BMC Cancer. 2025;25:1747.
   PubMed         Abstract available
   
   
10. MIZRACHI RP, Bouhnik D
    The parity paradox: does number of children (parity) influence breast cancer mortality across the life course?
    BMC Cancer. 2025;25:1750.
    PubMed         Abstract available
    
    

    
    Br J Cancer

11. NOVITSKI SI, Jacobsen RL, Roder T, Holm PC, et al
    Breast cancer risk prediction with a modified BOADICEA model in Danish women.
    Br J Cancer. 2025 Nov 12. doi: 10.1038/s41416-025-03247.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Dove Med Press)

12. MEGANTARA S, Rusdin A, Budiman A, Puluhulawa LE, et al
    Demonstrating the Absence of Correlation Between Molecular Docking and in vitro Cytotoxicity in Anti-Breast Cancer Research: Root Causes and Practical Resolutions.
    Breast Cancer (Dove Med Press). 2025;17:1005-1023.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

13. FERNANDEZ-MORATA J, Pollan M, Fernandez de Larrea-Baz N, Pachon-Olmos V, et al
    Correction: Mammographic density and breast cancer pathological subtypes by menopausal status and body mass index.
    Breast Cancer Res. 2025;27:201.
    PubMed        
    
    
14. YU S, Zhou Y, Zhang S, He F, et al
    The role and prognostic value of mitochondria-related gene PARK7 in breast cancer.
    Breast Cancer Res. 2025;27:200.
    PubMed         Abstract available
    
    
15. YANG Z, Lou H, Huang Y, Guo L, et al
    Integrating bulk and single-cell RNA sequencing analysis to reveal characterization of mechanical stimulus-related genes and prognostic signatures in breast cancer.
    Breast Cancer Res. 2025;27:204.
    PubMed         Abstract available
    
    
16. EDLUND J, Wu WY, Gustafsson M, Linden J, et al
    Exposure to ambient air pollution during pregnancy and risk of early-onset breast cancer.
    Breast Cancer Res. 2025;27:203.
    PubMed         Abstract available
    
    
17. JOUINES C, Lo Monaco P, Gaucherot A, Radermecker J, et al
    Fibrillarin-mediated ribosomal RNA maturation is a novel therapeutic vulnerability in triple-negative breast cancer.
    Breast Cancer Res. 2025;27:202.
    PubMed        
    
    

    
    Cancer Lett

18. VESUNA F, Winnard PT Jr, van Voss MH, Bol GM, et al
    Inhibition of DDX3 modulates immune signaling in aggressive breast cancers.
    Cancer Lett. 2025;634:218065.
    PubMed         Abstract available
    
    

    
    Cancer Res

19. YIN S, Liu Y, Guan X, Wang X, et al
    Tetraspanin 13 Enhances Immune Evasion in Breast Cancer by Promoting MHC-I Degradation.
    Cancer Res. 2025 Nov 11. doi: 10.1158/0008-5472.CAN-25-1223.
    PubMed         Abstract available
    
    
20. HOFER I, Kieffer Y, Mencattini A, Croizer H, et al
    An Extracellular Matrix-Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation.
    Cancer Res. 2025 Nov 12. doi: 10.1158/0008-5472.CAN-25-0966.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

21. OUYANG Z, Li S, Quan A
    Overall Survival and Related Clinicopathologic Features to Identify Low-Risk Patients With Early Breast Cancer Suitable For Radiation Therapy Omission After Conservative Surgery: A Meta-Analysis.
    Clin Breast Cancer. 2025 Oct 13:S1526-8209(25)00293.
    PubMed         Abstract available
    
    
22. LI S, Tang G, Lin S, Guan X, et al
    High Thymidine Kinase 1 Activity Linked to Poor Breast Cancer Survival: A Systematic Review and Meta-Analysis.
    Clin Breast Cancer. 2025 Oct 17:S1526-8209(25)00296.
    PubMed         Abstract available
    
    
23. KANDZI JD, Englisch A, Boeer B, Hahn M, et al
    Reconciling Sentinel Node Omission with CDK4/6 Inhibitor Eligibility in HR+/HER2- Early Breast Cancer: A Real-World Cohort Analysis.
    Clin Breast Cancer. 2025 Oct 13:S1526-8209(25)00294.
    PubMed         Abstract available
    
    
24. VRANCKEN PEETERS NJMC, Heins MJ, Re G, Kok M, et al
    Long-Term Health Issues of Adolescent and Young Adult Breast Cancer Survivors.
    Clin Breast Cancer. 2025 Oct 22:S1526-8209(25)00299.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

25. KNUTSON KL, Abu-Fares H, Keating P, Block MS, et al
    A phase II trial to evaluate the safety and immunogenicity of two doses of a folate receptor alpha vaccine in patients with triple negative breast cancer.
    Clin Cancer Res. 2025 Nov 10. doi: 10.1158/1078-0432.CCR-25-2763.
    PubMed         Abstract available
    
    
26. HOWARD FM, Fasching PA, Santa-Maria CA, Lim E, et al
    Machine Learning-Based Prediction of Distant Recurrence Risk and Ribociclib Treatment Effect in HR+/HER2- Early Breast Cancer Using Real-World and NATALEE Data.
    Clin Cancer Res. 2025 Nov 10. doi: 10.1158/1078-0432.CCR-25-1946.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

27. RASSY E, Delaloge S, Karimi M, Truong T, et al
    Evaluating breast cancer screening consortium and MammoRisk plus polygenic risk score 313 for breast cancer risk prediction in UK Biobank.
    Eur J Cancer. 2025;231:116096.
    PubMed         Abstract available
    
    
28. WORTELBOER N, Kent S, Konings IR, van Ommen-Nijhof A, et al
    Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial.
    Eur J Cancer. 2025;231:116051.
    PubMed         Abstract available
    
    

    
    Histopathology

29. KAIN ZE, Baez-Navarro X, Linn SC, van Deurzen CHM, et al
    Decision-making in breast pathology reporting: the effect of clinical relevant thresholds.
    Histopathology. 2025;87:951-955.
    PubMed         Abstract available
    
    
30. SUN M, Fu L, Ren H, Wang J, et al
    Two similar but distinct types of breast acinar cell carcinoma: evidence from histological, immunohistochemical and molecular features.
    Histopathology. 2025;87:904-914.
    PubMed         Abstract available
    
    
31. STA INES FM, Eadara A, Quddus MR, Sung CJ, et al
    Re-appraisal of mucocele-like lesion of the breast with atypia: study of 34 cases with focus on impact of type and extent of atypia on upgrade.
    Histopathology. 2025;87:943-950.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

32. DE LAURENTIIS M, Buonaiuto R, Buono G, Caputo R, et al
    In Defense of Adjuvant CDK4/6 Inhibitors in Early Breast Cancer.
    J Clin Oncol. 2025 Nov 7:JCO2501440. doi: 10.1200/JCO-25-01440.
    PubMed        
    
    

    
    J Natl Cancer Inst

33. VO JB, Brown DW, Buller ID, Shing JZ, et al
    Associations of self-identified race and ethnicity and genetic ancestry with mortality among cancer survivors.
    J Natl Cancer Inst. 2025;117:2382-2387.
    PubMed         Abstract available
    
    
34. LIU Q, Wiese D, Pinheiro PS, Bispo JB, et al
    Association between racialized economic segregation and stage at diagnosis for 3 screenable cancers in New York City.
    J Natl Cancer Inst. 2025;117:2259-2271.
    PubMed         Abstract available
    
    
35. ORLANDI A
    RE: Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer.
    J Natl Cancer Inst. 2025 Nov 5:djaf319. doi: 10.1093.
    PubMed        
    
    

    
    J Pathol

36. LLINARES-BURGUET I, Sanoguera-Miralles L, Bueno-Martinez E, Garcia-Alvarez A, et al
    Generation of functional noncanonical donor splice sites by +2T variants in breast cancer susceptibility genes: impact on clinical interpretation.
    J Pathol. 2025 Nov 13. doi: 10.1002/path.6497.
    PubMed         Abstract available
    
    
37. RYAN L, Provenzano E, Grigoriadis A, Pinder SE, et al
    Issues and missed opportunities in lymph node assessment after neoadjuvant chemotherapy.
    J Pathol. 2025;267:374-384.
    PubMed         Abstract available
    
    

    
    Nat Rev Clin Oncol

38. KILLOCK D
    T-DXd shows promise in neoadjuvant therapy for HER2(+) breast cancer.
    Nat Rev Clin Oncol. 2025 Nov 10. doi: 10.1038/s41571-025-01103.
    PubMed        
    
    

    
    NPJ Breast Cancer

39. NI M, Wang D, Dun S, Zhou Q, et al
    Real-world outcomes of trastuzumab deruxtecan in HR-negative HER2-low metastatic breast cancer.
    NPJ Breast Cancer. 2025;11:123.
    PubMed         Abstract available
    
    
40. LEE H, Kim N, Kim S, Kim JY, et al
    Clinical and genetic predictors of persistent chemotherapy-induced alopecia despite scalp cooling in breast cancer.
    NPJ Breast Cancer. 2025;11:124.
    PubMed         Abstract available
    
    
41. THOMAS A, Rhoads A, Mayer EL, O'Reilly S, et al
    Evolving incidence patterns for locally advanced operable breast cancer by receptor status: SEER 2010-2021.
    NPJ Breast Cancer. 2025;11:127.
    PubMed         Abstract available
    
    

    
    Oncogene

42. MEDKOUR Y, Dufour CR, Han L, Hutton P, et al
    Regulation of ribosomal gene expression and senescence by a PML-mTOR-RONIN nuclear complex in triple-negative breast cancer.
    Oncogene. 2025 Nov 8. doi: 10.1038/s41388-025-03623.
    PubMed         Abstract available
    
    
43. CHEN S, Xiang L, He M, Han Q, et al
    Chaperone-mediated autophagy controlling VEGFR1 degradation contributes cross talk between breast cancer cells and endothelial cells triggering tumorigenesis via the VEGF-VEGFR2 axis.
    Oncogene. 2025 Nov 13. doi: 10.1038/s41388-025-03619.
    PubMed         Abstract available
    
    

    
    PLoS One

44. BOUSQUET M, Lange M, Lequesne J, Durand-Zaleski I, et al
    Remotely supervised online cognitive training to reduce cognitive difficulties following chemotherapy in patients treated for localized breast cancer: Protocol of the Cog-Stim2 multicenter randomized controlled trial.
    PLoS One. 2025;20:e0335124.
    PubMed         Abstract available
    
    
45. ABEBE M, Asgedom YS, Gebrekidan AY, Tebeje TM, et al
    Factors influencing breast cancer screening among reproductive age women in Lesotho: Analysis of the 2023-24 demographic and health survey using the Andersen Behavioral Model.
    PLoS One. 2025;20:e0336983.
    PubMed         Abstract available
    
    
46. SMOTHERMAN C, Sprague BL, Braithwaite D, Yaghjyan L, et al
    Greenness and its interaction with air pollution in relation to postmenopausal breast cancer risk in UK Biobank.
    PLoS One. 2025;20:e0334744.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

47. WU CCN, De Luna N, Hairston E, Jeffs ED, et al
    FZD7 expression marks mammary tumor-initiating cells.
    Proc Natl Acad Sci U S A. 2025;122:e2522465122.
    PubMed         Abstract available
    
    
48. LI Y, Qiu X, Sandusky Z, Tagliaferri K, et al
    METTL3-dependent m6A RNA methylation suppresses aberrant mammary epithelial differentiation and neoplastic transformation.
    Proc Natl Acad Sci U S A. 2025;122:e2514643122.
    PubMed         Abstract available
    
    
49. WANG Z, Zeng Y, Tan Z, Chen Y, et al
    A unified framework for identification of cell-type-specific spatially variable genes in spatial transcriptomic studies.
    Proc Natl Acad Sci U S A. 2025;122:e2503952122.
    PubMed         Abstract available
    
    

    
    Radiol Artif Intell

50. LOTTER W, Hippe DS, Oshiro T, Lowry KP, et al
    Influence of Mammography Acquisition Parameters on AI and Radiologist Interpretive Performance.
    Radiol Artif Intell. 2025 Sep 17:e240861. doi: 10.1148/ryai.240861.
    PubMed         Abstract available
    
    

    
    Radiologia (Engl Ed)

51. ARENAS RIVERA EN, Alcantara R, Maiques JM, Macia F, et al
    Association of high breast density with adverse effects of the breast cancer screening program: A retrospective study.
    Radiologia (Engl Ed). 2025;67:101618.
    PubMed         Abstract available
    
    

    
    Radiother Oncol

52. MALONE C, Ryan S, Nicholson J, Brennan S, et al
    From rugged ridges to radiotherapy ROIs: Translating topographical metrics to Surface-Guided Radiation Therapy regions of Interest in radiotherapy.
    Radiother Oncol. 2025;213:111173.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.